Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study

Oncology Letters

Volumn 11, Issue 2, 2016, Pages 1021-1025

  Hafsi, Sameh ^a,b   Candido, Saverio ^a   Maestro, Roberta ^c   Falzone, Luca ^a   Soua, Zora ^b   Bonavida, Benjamin ^d   Spandidos, Demetrios A ^e   Libra, Massimo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SOUSSE   (Tunisia)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CRETE   (Greece)

Author keywords

Burkitt's lymphoma; Hsa miR 200a; Hsa miR 363; Yin Yang 1

Indexed keywords

CD19 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; MICRORNA; MICRORNA 15A; MICRORNA 15B; MICRORNA 200A; MICRORNA 23B; MICRORNA 363; TRANSCRIPTION FACTOR YY1; UNCLASSIFIED DRUG;

ARTICLE; BURKITT LYMPHOMA; COMPUTER ANALYSIS; CORRELATION ANALYSIS; DATA ANALYSIS SOFTWARE; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE; NONHODGKIN LYMPHOMA; TONSIL; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84954338895     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.4031     Document Type: Article

References (44)

1. Baek D, Villén J, Shin C, Camargo FD, Gygi SP and Bartel DP: The impact of microRNAs on protein output. Nature 455: 64-71, 2008.
2. Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233, 2009.
3. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack FJ: RAS is regulated by the let-7 microRNA family. Cell 120: 635-647, 2005.
4. Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4: 143-159, 2012.
5. Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol 9: 287-314, 2014.
6. Jaffe ES: The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009: 523-531, 2009.
7. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A and Arnesen M: Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med 316: 79-84, 1987.
8. Ansell SM: Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clin Proc 90: 1152-1163, 2015.
9. Mehta-Shah N and Younes A: Novel targeted therapies in diffuse large B-cell lymphoma. Semin Hematol 52: 126-137, 2015.
10. Vega MI, Jazirehi AR, Huerta-Yepez S and Bonavida B: Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 175: 2174-2183, 2005.
11. Gordon S, Akopyan G, Garban H and Bonavida B: Transcription factor YY1: Structure, function, and therapeutic implications in cancer biology. Oncogene 25: 1125-1142, 2006.
12. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, McCubrey JA, Canevari S and Libra M: The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle 8: 1367-1372, 2009.
13. Bonavida B, Huerta-Yepez S, Baritaki S, Vega M, Liu H, Chen H and Berenson J: Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies. Crit Rev Oncog 16: 261-267, 2011.
14. Castellano G, Torrisi E, Ligresti G, Nicoletti F, Malaponte G, Traval S, McCubrey JA, Canevari S and Libra M: Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. Cell Cycle 9: 557-563, 2010.
15. Maragkakis M, Alexiou P, Papadopoulos GL, Reczko M, Dalamagas T, Giannopoulos G, Goumas G, Koukis E, Kourtis K, Simossis VA, et al: Accurate microRNA target prediction correlates with protein repression levels. BMC Bioinformatics 10: 295, 2009.
16. John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Correction: Human MicroRNA targets. PLoS Biol 3:e264, 2005.
17. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al: Combinatorial microRNA target predictions. Nat Genet 37: 495-500, 2005.
18. Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife 4: e05005, 2015.
19. Bueno MJ, Gómez de Cedrón M, Gómez-López G, Pérez de Castro I, Di Lisio L, Montes-Moreno S, Martínez N, Guerrero M, Sánchez-Martínez R, Santos J, et al: Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. Blood 117: 6255-6266, 2011.
20. Di Lisio L, Sánchez-Beato M, Gómez-López G, Rodríguez ME, Montes-Moreno S, Mollejo M, Menárguez J, Martínez MA, Alves FJ, Pisano DG, et al: MicroRNA signatures in B-cell lymphomas. Blood Cancer J 2: e57, 2012.
21. Troppan K, Wenzl K, Deutsch A, Ling H, Neumeister P and Pichler M: MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 34: 557-564, 2014.
22. Musilova K and Mraz M: MicroRNAs in B-cell lymphomas: How a complex biology gets more complex. Leukemia 29: 1004-1017, 2015.
23. Garofalo M, Leva GD and Croce CM: MicroRNAs as anti-cancer therapy. Curr Pharm Des 20: 5328-5335, 2014.
24. Lim EL, Trinh DL, Scott DW, Chu A, Krzywinski M, Zhao Y, Robertson AG, Mungall AJ, Schein J, Boyle M, et al: Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. Genome Biol 16: 18, 2015.
25. Shi Y, Seto E, Chang LS and Shenk T: Transcriptional repression by YY1, a human GLI-Krüppel-related protein, and relief of repression by adenovirus E1A protein. Cell 67: 377-388, 1991.
26. Lee HY, Chaudhary J, Walsh GL, Hong WK and Kurie JM: Suppression of c-Fos gene transcription with malignant transformation of human bronchial epithelial cells. Oncogene 16: 3039-3046, 1998.
27. Liao WR, Hsieh RH, Hsu KW, Wu MZ, Tseng MJ, Mai RT, Wu Lee YH and Yeh TS: The CBF1-independent Notch1 signal pathway activates human c-myc expression partially via transcription factor YY1. Carcinogenesis 28: 1867-1876, 2007.
28. Allouche A, Nolens G, Tancredi A, Delacroix L, Mardaga J, Fridman V, Winkler R, Boniver J, Delvenne P and Begon DY: The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Res 10: R9, 2008.
29. Begon DY, Delacroix L, Vernimmen D, Jackers P and Winkler R: Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem 280: 24428-24434, 2005.
30. Wan M, Huang W, Kute TE, Miller LD, Zhang Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, et al: Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol 180: 2120-2133, 2012.
31. Rayess H, Wang MB and Srivatsan ES: Cellular senescence and tumor suppressor gene p16. Int J Cancer 130: 1715-1725, 2012.
32. Wu S, Murai S, Kataoka K and Miyagishi M: Cooperative regulation og p73 promoter by Yin Yang 1 and E2F1. Nucleic Acids Symp Ser (Oxf) 51: 347-348, 2007.
33. Grönroos E, Terentiev AA, Punga T and Ericsson J: YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci USA 101: 12165-12170, 2004.
34. Migliazza A, Martinotti S, Chen W, Fusco C, Ye BH, Knowles DM, Offit K, Chaganti RS and Dalla-Favera R: Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci USA 92: 12520-12524, 1995.
35. Libra M, Torrisi E, Castellano G, Nicoletti F, Malaponte G, Mazzarino MC, Marconi A, Proietti L, Militello L, Bonavida B, et al: Computational Evaluation of Yin Yang 1 Transcript Levels in the Spectrum of B-cell Neoplasia. Immunopathol Dis Therap 1: 115-125, 2010.
36. Sui G, Affar B, Shi Y, Brignone C, Wall NR, Yin P, Donohoe M, Luke MP, Calvo D, Grossman SR, et al: Yin Yang 1 is a negative regulator of p53. Cell 117: 859-872, 2004.
37. Affar B, Gay F, Shi Y, Liu H, Huarte M, Wu S, Collins T, Li E and Shi Y: Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression. Mol Cell Biol 26: 3565-3581, 2006.
38. Maestro R, Gloghini A, Doglioni C, Piccinin S, Vukosavljevic T, Gasparotto D, Carbone A and Boiocchi M: Human non-Hodgkin's lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21. Blood 89: 2523-2528, 1997.
39. Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG, Jin DY, Costello JF and Liang R: Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 31: 745-750, 2010.
40. McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong EW, Steelman LS, Bäsecke J, Troppmair J, Libra M, Nicoletti F, et al: Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 22: 2080-2090, 2008.
41. van Kempen LC, van den Hurk K, Lazar V, Michiels S, Winnepenninckx V, Stas M, Spatz A and van den Oord JJ: Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression. Virchows Arch 461: 441-448, 2012.
42. Cai J, Liu X, Cheng J, Li Y, Huang X, Li Y, Ma X, Yu H, Liu H and Wei R: MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2. Graefes Arch Clin Exp Ophthalmol 250: 523-531, 2012.
43. Sandhu SK, Croce CM and Garzon R: Micro-RNA expression and function in lymphomas. Adv Hematol 2011: 347137, 2011.
44. Zou J, Yin F, Wang Q, Zhang W and Li L: Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol 8: 6847-6858, 2015.